trending Market Intelligence /marketintelligence/en/news-insights/trending/D1OvnyT_N3AZaHfZaFyl5Q2 content esgSubNav
In This List

Eidos Therapeutics appoints former Portola executive to board

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Eidos Therapeutics appoints former Portola executive to board

Eidos Therapeutics Inc. appointed William Lis to its board, effective Dec. 4.

Lis recently was CEO and a director of biopharmaceutical company Portola Pharmaceuticals Inc.

Additionally, Hoyoung Huh stepped down as a director of Eidos.

Eidos Therapeutics is a clinical-stage biopharmaceutical company that develops drugs to treat diseases caused by the neurodegenerative disease transthyretin amyloidosis.